<?xml version='1.0' encoding='utf-8'?>
<document id="11497338"><sentence text="Study of the drug-drug interaction between simvastatin and cisapride in man."><entity charOffset="43-54" id="DDI-PubMed.11497338.s1.e0" text="simvastatin" /><entity charOffset="59-68" id="DDI-PubMed.11497338.s1.e1" text="cisapride" /><pair ddi="false" e1="DDI-PubMed.11497338.s1.e0" e2="DDI-PubMed.11497338.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11497338.s1.e0" e2="DDI-PubMed.11497338.s1.e1" /></sentence><sentence text="The objective of our study was to evaluate in humans the drug-drug interaction occurring during the concomitant administration of cisapride and simvastatin, two well-known substrates of CYP3A4"><entity charOffset="130-139" id="DDI-PubMed.11497338.s2.e0" text="cisapride" /><entity charOffset="144-155" id="DDI-PubMed.11497338.s2.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.11497338.s2.e0" e2="DDI-PubMed.11497338.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11497338.s2.e0" e2="DDI-PubMed.11497338.s2.e1" /></sentence><sentence text="" /><sentence text="Eleven healthy men aged between 20 years and 35 years gave their written informed consent to participate in the study" /><sentence text=" Each participant received repeated doses of cisapride and/or simvastatin"><entity charOffset="45-54" id="DDI-PubMed.11497338.s5.e0" text="cisapride" /><entity charOffset="62-73" id="DDI-PubMed.11497338.s5.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.11497338.s5.e0" e2="DDI-PubMed.11497338.s5.e0" /><pair ddi="false" e1="DDI-PubMed.11497338.s5.e0" e2="DDI-PubMed.11497338.s5.e1" /></sentence><sentence text=" At first, subjects received cisapride alone, 10 mg every 8 h, for 3 days"><entity charOffset="29-38" id="DDI-PubMed.11497338.s6.e0" text="cisapride" /></sentence><sentence text=" Then, the drug was given at the same regimen during concomitant administration of simvastatin, 20 mg every 12 h for 4 days, starting on the night of day 3"><entity charOffset="83-94" id="DDI-PubMed.11497338.s7.e0" text="simvastatin" /></sentence><sentence text=" Finally, cisapride was stopped and subjects received simvastatin (20 mg every 12 h) for four additional days"><entity charOffset="10-19" id="DDI-PubMed.11497338.s8.e0" text="cisapride" /><entity charOffset="54-65" id="DDI-PubMed.11497338.s8.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.11497338.s8.e0" e2="DDI-PubMed.11497338.s8.e0" /><pair ddi="false" e1="DDI-PubMed.11497338.s8.e0" e2="DDI-PubMed.11497338.s8.e1" /></sentence><sentence text="" /><sentence text="Simvastatin administration caused a 14 +/- 20% increase in the AUC0-8 of cisapride"><entity charOffset="0-11" id="DDI-PubMed.11497338.s10.e0" text="Simvastatin" /><entity charOffset="73-82" id="DDI-PubMed.11497338.s10.e1" text="cisapride" /><pair ddi="false" e1="DDI-PubMed.11497338.s10.e0" e2="DDI-PubMed.11497338.s10.e0" /><pair ddi="false" e1="DDI-PubMed.11497338.s10.e0" e2="DDI-PubMed.11497338.s10.e1" /></sentence><sentence text=" In contrast, plasma concentrations of simvastatin were unaltered by the coadministration of cisapride, whereas plasma concentrations of simvastatin acid, its active metabolite, were decreased by 33 +/- 24%"><entity charOffset="39-50" id="DDI-PubMed.11497338.s11.e0" text="simvastatin" /><entity charOffset="93-102" id="DDI-PubMed.11497338.s11.e1" text="cisapride" /><entity charOffset="137-153" id="DDI-PubMed.11497338.s11.e2" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.11497338.s11.e0" e2="DDI-PubMed.11497338.s11.e0" /><pair ddi="false" e1="DDI-PubMed.11497338.s11.e0" e2="DDI-PubMed.11497338.s11.e1" /><pair ddi="false" e1="DDI-PubMed.11497338.s11.e0" e2="DDI-PubMed.11497338.s11.e2" /><pair ddi="false" e1="DDI-PubMed.11497338.s11.e1" e2="DDI-PubMed.11497338.s11.e1" /><pair ddi="false" e1="DDI-PubMed.11497338.s11.e1" e2="DDI-PubMed.11497338.s11.e2" /></sentence><sentence text="" /><sentence text="The concomitant administration of the prokinetic agent cisapride and the 3-hydroxy-3-methylgluaryl CoA reductase inhibitor simvastatin resulted in altered pharmacokinetics of both drugs"><entity charOffset="55-64" id="DDI-PubMed.11497338.s13.e0" text="cisapride" /><entity charOffset="73-102" id="DDI-PubMed.11497338.s13.e1" text="3-hydroxy-3-methylgluaryl CoA" /><entity charOffset="123-134" id="DDI-PubMed.11497338.s13.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.11497338.s13.e0" e2="DDI-PubMed.11497338.s13.e0" /><pair ddi="false" e1="DDI-PubMed.11497338.s13.e0" e2="DDI-PubMed.11497338.s13.e1" /><pair ddi="false" e1="DDI-PubMed.11497338.s13.e0" e2="DDI-PubMed.11497338.s13.e2" /><pair ddi="false" e1="DDI-PubMed.11497338.s13.e1" e2="DDI-PubMed.11497338.s13.e1" /><pair ddi="false" e1="DDI-PubMed.11497338.s13.e1" e2="DDI-PubMed.11497338.s13.e2" /></sentence><sentence text=" Increased plasma concentrations of cisapride suggest that some patients may be at risk of toxicity while receiving both drugs, whereas the decrease in simvastatin acid plasma concentrations suggests that cholesterol lowering effects of simvastatin treatment may be blunted"><entity charOffset="36-45" id="DDI-PubMed.11497338.s14.e0" text="cisapride" /><entity charOffset="152-168" id="DDI-PubMed.11497338.s14.e1" text="simvastatin acid" /><entity charOffset="205-216" id="DDI-PubMed.11497338.s14.e2" text="cholesterol" /><entity charOffset="237-248" id="DDI-PubMed.11497338.s14.e3" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e0" e2="DDI-PubMed.11497338.s14.e0" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e0" e2="DDI-PubMed.11497338.s14.e1" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e0" e2="DDI-PubMed.11497338.s14.e2" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e0" e2="DDI-PubMed.11497338.s14.e3" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e1" e2="DDI-PubMed.11497338.s14.e1" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e1" e2="DDI-PubMed.11497338.s14.e2" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e1" e2="DDI-PubMed.11497338.s14.e3" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e2" e2="DDI-PubMed.11497338.s14.e2" /><pair ddi="false" e1="DDI-PubMed.11497338.s14.e2" e2="DDI-PubMed.11497338.s14.e3" /></sentence><sentence text="" /></document>